Bladder Cancer最新文献

筛选
英文 中文
Challenging Cases in Urothelial Cancer: Case 32 泌尿道癌的挑战性病例:病例 32
Bladder Cancer Pub Date : 2024-06-13 DOI: 10.3233/blc-249004
M. S. Soloway, Neil A. Abrahams
{"title":"Challenging Cases in Urothelial Cancer: Case 32","authors":"M. S. Soloway, Neil A. Abrahams","doi":"10.3233/blc-249004","DOIUrl":"https://doi.org/10.3233/blc-249004","url":null,"abstract":"","PeriodicalId":505480,"journal":{"name":"Bladder Cancer","volume":"5 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141349625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Trials Corner Issue 10(2) 临床试验园地》第 10(2)期
Bladder Cancer Pub Date : 2024-06-12 DOI: 10.3233/blc-249006
P. Agarwal, Cora N. Sternberg
{"title":"Clinical Trials Corner Issue 10(2)","authors":"P. Agarwal, Cora N. Sternberg","doi":"10.3233/blc-249006","DOIUrl":"https://doi.org/10.3233/blc-249006","url":null,"abstract":"","PeriodicalId":505480,"journal":{"name":"Bladder Cancer","volume":"19 22","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141354537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer – Clinical Activity and Whole Transcriptome Analysis 肉瘤型膀胱癌新辅助治疗顺铂、吉西他滨和多西他赛--临床活性和全转录组分析
Bladder Cancer Pub Date : 2024-05-20 DOI: 10.3233/blc-240008
Burles A. Johnson III, Benjamin A. Teply, Catherine Kagemann, B. McGuire, Kara Lombardo, Yuezhou Jing, William Langbo, Jonathan I. Epstein, George J. Netto, A. Baras, A. Matoso, D. McConkey, Amol Gupta, Nita Ahuja, Ashley E. Ross, Phillip M. Pierorazio, Eva Compérat, J. Hoffman-Censits, N. Singla, Sunil H. Patel, M. Kates, W. Choi, T. Bivalacqua, Noah M. Hahn
{"title":"Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer – Clinical Activity and Whole Transcriptome Analysis","authors":"Burles A. Johnson III, Benjamin A. Teply, Catherine Kagemann, B. McGuire, Kara Lombardo, Yuezhou Jing, William Langbo, Jonathan I. Epstein, George J. Netto, A. Baras, A. Matoso, D. McConkey, Amol Gupta, Nita Ahuja, Ashley E. Ross, Phillip M. Pierorazio, Eva Compérat, J. Hoffman-Censits, N. Singla, Sunil H. Patel, M. Kates, W. Choi, T. Bivalacqua, Noah M. Hahn","doi":"10.3233/blc-240008","DOIUrl":"https://doi.org/10.3233/blc-240008","url":null,"abstract":"Background: Sarcomatoid urothelial cancer of the bladder (SBC) is a rare, but aggressive histological subtype for which novel treatments are needed. Objective: We evaluated the clinical activity and safety of neoadjuvant cisplatin plus gemcitabine plus docetaxel (CGD) in muscle-invasive patients with SBC and assessed SBC tumor biology by whole transcriptome RNA sequencing. Methods: A single-institution, retrospective analysis of muscle-invasive SBC patients treated with neoadjuvant CGD with molecular analysis. Patients received cisplatin 35 mg/m2 + gemcitabine 800 mg/m2 + docetaxel 35 mg/m2 intravenously on days 1 and 8 + pegfilgrastim 6 mg subcutaneously on day 9 every 3 weeks for 4 cycles followed by cystectomy. The primary endpoint was pathologic complete response (ypCR) rate. Results: Sixteen patients with SBC received neoadjuvant CGD with a ypCR rate of 38% and a < ypT2 rate of 50%. Grade 3 and 4 toxicity occurred in 80% and 40% of patients, but was manageable with 81% of patients completing > 3 CGD cycles. Whole transcriptome RNA sequencing demonstrates co-clustering of SBC with conventional urothelial tumors. SBC tumors are characterized by basal-squamous and stroma rich gene signatures with frequent increased expression of immune checkpoint (CD274 (PD-L1)), chemokine (CXCL9), and T-cell (CD8A) genes. Conclusions: SBC is a chemosensitive subtype, with ypCR rate similar to urothelial bladder cancer following CGD neoadjuvant therapy. Whole transcriptome tissue analyses demonstrate increased expression of immune checkpoint and T-cell genes with therapeutic implications.","PeriodicalId":505480,"journal":{"name":"Bladder Cancer","volume":"57 19","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141121681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-muscle invasive bladder cancer: Many more patients die with it than of it 非肌层浸润性膀胱癌:死于非肌层浸润性膀胱癌的患者比死于膀胱癌的患者多得多
Bladder Cancer Pub Date : 2024-05-20 DOI: 10.3233/blc-230099
Kathryn E. McGonagle, Ellen J. Dematt, Zhibao Mi, Kousick Biswas, Florian R. Schroeck
{"title":"Non-muscle invasive bladder cancer: Many more patients die with it than of it","authors":"Kathryn E. McGonagle, Ellen J. Dematt, Zhibao Mi, Kousick Biswas, Florian R. Schroeck","doi":"10.3233/blc-230099","DOIUrl":"https://doi.org/10.3233/blc-230099","url":null,"abstract":"BACKGROUND: The National Cancer Institute SEER Program regularly publishes bladder-cancer specific survival statistics. However, this data is for all bladder cancers, and information for non-muscle invasive bladder cancer (NMIBC) is difficult to obtain. OBJECTIVE: To quantify 5-year overall and bladder cancer-specific survival in a cohort of Department of Veterans Affairs (VA) patients diagnosed with NMIBC. METHODS: We identified VA patients diagnosed with NMIBC who underwent a transurethral resection from 2003-2013. The patient demographics and Charlson Comorbidity Index were categorized. We acquired the patients’ date of death from the Veterans Health Administration’s Death Ascertainment File and their cause of death from the Mortality Data Repository. We calculated Kaplan Meier estimates of survival. RESULTS: A total of 27,008 patients were included; median age was 69 and almost all were male (99%). The median comorbidity score was 4. The most prevalent comorbidity indicators included Chronic Pulmonary Disease (48%), cancer other than Bladder (41%), and diabetes (40%). This cohort was found to have a 5-year overall survival of 68% (99% CI 67% –69%) and a 5-year bladder cancer-specific survival of 93% (99% CI 92% –94%). CONCLUSIONS: The 5-year bladder cancer-specific survival in patients diagnosed with non-muscle invasive bladder cancer is substantially higher than the 5-year overall survival. This difference may be related to the severity and number of comorbidities that patients in this population must manage. This warrants further research into the necessity of currently recommended high-intensity cancer surveillance for individuals with NMIBC.","PeriodicalId":505480,"journal":{"name":"Bladder Cancer","volume":"26 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141120497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenging Cases in Urothelial Cancer: Case 31: LG Ta Bladder Cancer 泌尿道癌的挑战性病例:病例 31:LG Ta 膀胱癌
Bladder Cancer Pub Date : 2024-02-27 DOI: 10.3233/blc-249002
Mark S. Soloway, Neil A. Abrahams
{"title":"Challenging Cases in Urothelial Cancer: Case 31: LG Ta Bladder Cancer","authors":"Mark S. Soloway, Neil A. Abrahams","doi":"10.3233/blc-249002","DOIUrl":"https://doi.org/10.3233/blc-249002","url":null,"abstract":"","PeriodicalId":505480,"journal":{"name":"Bladder Cancer","volume":"80 S1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140427069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenging Cases in Urothelial Cancer: Case 30: Rare complication of BCG 泌尿道癌的挑战性病例:病例 30:卡介苗罕见并发症
Bladder Cancer Pub Date : 2023-11-17 DOI: 10.3233/blc-239010
M. S. Soloway
{"title":"Challenging Cases in Urothelial Cancer: Case 30: Rare complication of BCG","authors":"M. S. Soloway","doi":"10.3233/blc-239010","DOIUrl":"https://doi.org/10.3233/blc-239010","url":null,"abstract":"","PeriodicalId":505480,"journal":{"name":"Bladder Cancer","volume":"25 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139266184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信